Get started
Author

Domenico Roberti

TIMELESS Forms a Complex with PARP1 Distinct from Its Complex with TIPIN and Plays a Role in the DNA Damage Response
2015 · Lauren M. Young, Antonio Marzio, et al. · Cell Reports · 83
PDF
PARP1-dependent recruitment of the FBXL10-RNF68-RNF2 ubiquitin ligase to sites of DNA damage controls H2A.Z loading
2018 · Gergely Rona, Domenico Roberti, et al. · eLife · 55
Recent BCR stimulation induces a negative autoregulatory loop via FBXO10 mediated degradation of HGAL
2019 · Fengjie Guo, Yuan Luo, et al. · Leukemia · 17
Abstract LB_A12: Initial results from 2 Phase I studies of NMS-03305293, a selective PARP1 inhibitor
2023 · Marjolein Geurts, Dorothee Gramatzki, et al. · Molecular Cancer Therapeutics · 6
NMS-01940153E, an MPS1 inhibitor with anti-tumor activity in relapsed or refractory unresectable Hepatocellular carcinoma
2022 · M. Reig, S. Damian, et al. · European Journal of Cancer · 1
PARPA-293-003: A phase 1a/1b, multicenter, open-label study of NMS-03305293 (itareparib), a non-trapping PARP1-selective inhibitor, in combination with topotecan in patients with recurrent platinum-resistant ovarian cancer
2026 · Ravali Reddy, Amir Jazaeri, et al. · Gynecologic Oncology
58TiP PARPA-293-004: Phase Ib study of NMS-03305293, a brain-penetrant, non-trapping PARP1-selective inhibitor, in combination with temozolomide in relapsed ES-small cell lung cancer
2026 · D. Roberti, C. Meador, et al. · ESMO Open
PDF
57TiP PARPA-293-003: Phase Ia/Ib study of NMS-03305293 (Itareparib), a brain-penetrant, non-trapping PARP1-selective inhibitor, in combination with topotecan in recurrent HR proficient platinum-resistant/refractory ovarian cancer
2026 · D. Roberti, A. Jazaeri, et al. · ESMO Open
Abstract 509: The MPS1/TTK inhibitor, NMS-01940153, synergizes with tisotumab vedotin in colorectal cancer
2024 · Gemma Texido, Fabio Gasparri, et al. · Cancer Research
Phase II study on safety and efficacy of NMS-01940153E, an MPS1 inhibitor with first-in-class potential, in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy.
2023 · Lorenza Rimassa, Maria Reig, et al. · Journal of Clinical Oncology
Author response: PARP1-dependent recruitment of the FBXL10-RNF68-RNF2 ubiquitin ligase to sites of DNA damage controls H2A.Z loading
2018 · Gergely Rona, Domenico Roberti, et al.
FBXO10 Targets HGAL for Degradation
2015 · Fengjie Guo, Xiaoyu Jiang, et al. · Blood
Faculty Opinions recommendation of APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction.
2014 · Michele Pagano, Domenico Roberti · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
Faculty Opinions recommendation of Control of epithelial cell migration and invasion by the IKKβ- and CK1α-mediated degradation of RAPGEF2.
2014 · Michele Pagano, Domenico Roberti · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
Faculty Opinions recommendation of Microtubule-dependent regulation of mitotic protein degradation.
2014 · Michele Pagano, Domenico Roberti · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
Faculty Opinions recommendation of KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.
2013 · Michele Pagano, Domenico Roberti · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
Works count: 21
Citation count: 162
H-index: 4
I10-index: 3
Year
Topic
Type